{"entity":{"id":"nct02477696","kind":"trial","name":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","aka":[],"tldr":"A phase 3 trial of Acalabrutinib and Ibrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.","summary":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT02477696 by Acerta Pharma BV, with 533 participants enrolled, started 2015-07-28 and due to reach its primary completion in 2020-09-15. Interventions recorded: Acalabrutinib and Ibrutinib. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02477696","url":"https://clinicaltrials.gov/study/NCT02477696"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll","cll-relapsed"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["acalabrutinib","ibrutinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02477696","phase":"3","setting":"A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia","sponsor":"Acerta Pharma BV","started":"2015-07-28","startedType":"actual","yearReported":2022,"enrolled":533,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment","primary":true,"unit":"months","arms":[{"name":"Acalabrutinib","n":268,"value":38.4,"note":"95% CI 33.0 to 38.6; Figures from the ClinicalTrials.gov results section (first posted 2022-01-28), not from a publication"},{"name":"Ibrutinib","n":265,"value":38.4,"note":"95% CI 33.0 to 41.6"}],"hr":1,"ci":[0.79,1.27],"source":"https://clinicaltrials.gov/study/NCT02477696?tab=results"}]},"route":"/trials/nct02477696/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}